PRL and Parkinson disease: Here, we report preclinical evidence that TAK‐063 may be beneficial as combination therapy with current antipsychotics without effects on plasma prolactin levels and cataleptic responses, which may be indicative of propensity to cause EPS such as drug‐induced Parkinsonism.18